

# HSP90: A New Recruit in the War on Cancer

Thus, when HSP90 (along with another 50 kDa cellular protein) were described to co-immunoprecipitate with the transforming protein expressed by Rous sarcoma virus, pp60src (v-src), investigators were puzzled. How and why was a cellular protein like HSP90 being recruited by one of the first discovered oncogenic proteins?

While the relevance of this HSP90-pp60src interaction remained elusive, papers reporting HSP90 as a partner for a large cadre of other important cellular proteins began to populate the literature. The list of these so-called HSP90 “clients” is now quite large, but can be grouped into three broad classes: i) transcription factors and in particular, members of the steroid hormone receptor family; ii) Protein kinases, many of which are involved in cellular proliferation pathways; iii) other seemingly unrelated proteins (at least at the structural level) involved in viral replication and innate immunity.

Investigators probing the connection of HSP90 with steroid hormone receptors paved the way for much of our current understanding of HSP90 function. Work performed in a number of different laboratories showed that the steroid hormone receptors, during or shortly following their synthesis in the cytoplasm, rapidly associated with HSP90. Somehow HSP90 appeared to ready the receptor for its subsequent hormone-dependent activation. Now 25 years later, the details of how HSP90 and its host of co-chaperones facilitate hormone receptor maturation have emerged. The newly synthesized steroid receptor is first targeted by the HSP40/HSP70 chaperone machinery. All of the available evidence indicates that these early binding chaperones target the hormone-binding site of the receptor, thereby preventing its premature interaction with the ligand. This ternary complex is then presented to HSP90 and a co-chaperone Hop. Shortly thereafter additional HSP90 co-chaperones are also recruited to the complex (e.g., p23, a family of tetratricopeptide repeat (TPR) proteins, and likely others). This complex series of assembly events, all requiring ATP binding/hydrolysis, result in a folded receptor now competent to bind to its activating steroid hormone ligand. Binding of the hormone results in a conformational change of the receptor, release of at least some of its chaperone partners, and the ability of the now “transformed” receptor to bind to DNA. Receptor binding to its target gene(s) requires additional interactions with transcriptional co-regulator proteins and various posttranslational modifications, all mediated at least in part by various members of the chaperone family.

This model wherein HSP90, along with its cadre of co-chaperones, facilitates the synthesis and activation of steroid hormone receptors appears to apply to other HSP90 clients. In addition, other co-chaperones have been identified and may help to explain the diversity of client proteins that bind to HSP90. For example, in the case of pp60src, the normal cellular form of src (c-src) likely interacts first with the HSP40/HSP70 machinery. Cdc-37, a protein initially identified as being important in cell division, binds and presents the kinase to HSP90. Finally, the co-chaperone, p23, enters the fray. Through its influence on the rate of HSP90 ATPase activity, p23 presumably serves to stabilize the complex. Eventually src is released from the complex and is now fully active as a tyrosine-specific protein kinase. In the case of mutant and oncogenic forms of src (e.g. v-src), the HSP90/Cdc37/p23 complex containing the kinase appears longer-lived.

Although still not fully understood, the prolonged interaction of v-src with the HSP90 chaperone machinery appears to be essential for its enhanced oncogenic activity.

Protein kinases are now known to represent the single largest group of HSP90 clientele. Relevant examples include numerous receptor tyrosine kinases (e.g. EGFR, MET), non-receptor tyrosine kinases such as SRC and its relative LCK, many intracellular ser/thr kinases such as RAF, and a large number of kinases important for cell-cycle entry and progression. HSP90 also serves a role in regulating the activities of important protein kinases associated with apoptosis (e.g. AKT), tissue invasion/metastasis, and angiogenesis (e.g. MET). Although so many protein kinases have been shown to be dependent on HSP90 (and Cdc-37) for their function, the precise biochemical details by which HSP90 activates or influences the particular kinase still remains obscure. In vitro systems, like those developed to sort out HSP90’s role in steroid receptor maturation, will be necessary to define how HSP90 and its horde of co-factors ready protein kinases for their activation and regulation, both under normal growth conditions as well as during the development and/or maintenance of the transformed phenotype.

Key to our understanding of HSP90 structure and function, and helping in the identification of HSP90 clients, are a class of naturally occurring compounds that bind to and inhibit HSP90 function. Herbimycin and geldanamycin, benzoquinoid ansamycins, initially were observed to reverse the transformed phenotype in cells transformed by oncogenic associated tyrosine kinases (e.g. v-src) and therefore were suggested to be kinase inhibitors. Subsequent analysis however, established that these compounds instead bound to and inhibited HSP90. Interaction of these drugs with HSP90 was mapped to a novel ATP binding site near the N-terminus of HSP90. We now know that these and related compounds block the ATPase coupled chaperone cycle of HSP90 that is necessary for client maturation and function. In the absence of this chaperone cycle, the client protein is almost always destined for ubiquitination and subsequent degradation via the proteasome pathway. Thus, these drugs, along with genomic and proteomic approaches, have proven useful in helping identify the vast array of HSP90 clients in the cell. In addition, HSP90 inhibitors have proven most useful in deciphering important details regarding the structure and function of HSP90, and especially the role of ATP dependent cycling for client maturation.

The association of HSP90 with so many important proteins involved in signal transduction pathways has led to suggestions that it may be a target for cancer therapy. At first glance this suggestion seemed unwise due to concerns that the inhibition of such a ubiquitous chaperone involved in so many biological pathways likely would have an acutely toxic effect. On the other hand, the necessity of HSP90 for the activity of such a wide variety of proteins involved in oncogenesis suggested that it might represent a novel target for the treatment of many different types of cancer. Further encouraging this idea were studies showing that HSP90 inhibitors tended to accumulate at much higher levels in tumor tissues compared to normal tissues. Based on these observations, clinicians have recently begun to turn their attention to HSP90 as a potential target for the treatment of numerous types of neoplasia.

# HSP90 and Co-Chaperones

## Antibodies

Product	Specificity	Application	Prod. No.
<b>Grp94, mAb (9G10)</b>	H, M, R, B, C, CH, HA, GP, MO, P, RB, S, X	FC, IHC, WB	ADI-SPA-850
<b>Grp94, mAb (9G10) (DyLight™ 488 conjugate)</b>	H, M, R, B, C, CH, HA, GP, MO, P, RB, S, X	FC	ADI-SPA-850-488
<b>Grp94, mAb (9G10) (R-PE conjugate)</b>	H, M, R, B, C, CH, HA, GP, MO, RB, P, S, X	FC	ADI-SPA-850PE
<b>Grp94, pAb</b>	H, M, R, B	IP, WB	ADI-SPA-851
<b>HSP84, pAb</b>	H, M, R	ICC, IP, WB	ALX-210-138
<b>HSP86, pAb</b>	H, M, R, S	ICC, IHC, IP, WB	ALX-210-139
<b>HSP90 co-chaperone, mAb (JJ3)</b>	M, H	ICC, IP, WB	ALX-804-023
<b>HSP90, mAb (16F1)</b>	H, M, R, B, BE, C, CH, D, F, GP, HA, MO, MU, P, PL, RB, S, SC, X	WB	ADI-SPA-835
<b>HSP90, mAb (16F1) (biotin conjugate)</b>	H, M, R	WB	ADI-SPA-835B
<b>HSP90, mAb (2D12)</b>	H, M, R, BE, B, C, CH, F, GP, HA, MO, RB, S	WB	ADI-SPA-845
<b>HSP90, mAb (3B6)</b>	H, M, R, B	WB	ALX-804-078
<b>HSP90, mAb (3G3)</b>	H, M, R, CH, F	IP	ALX-804-079
<b>HSP90, mAb (AC88)</b>	H, M, R, BA, BE, C, CH, CE, F, GP, HA, MO, MU, P, RB, S, SC, WM	WB	ADI-SPA-830
<b>HSP90, mAb (AC88) (DyLight™ 488 conjugate)</b>	H, M, R, BE, C, CE, CH, F	FC	ADI-SPA-830-488
<b>HSP90, mAb (AC88) (R-PE conjugate)</b>	H, M, R, B, C, CH, F	FC	ADI-SPA-830PE
<b>HSP90, pAb</b>	H, M, R, RB	WB	ADI-SPA-836
<b>HSP90, pAb</b>	H, M, R, B	WB	ADI-SPA-846
<b>HSP90α, mAb (9D2)</b>	H, CH	FC, IHC, WB	ADI-SPA-840
<b>HSP90α, mAb (9D2) (HRP conjugate)</b>	H, CH	WB	ADI-SPA-840HRP
<b>HSP90α, pAb</b>	H, M, R, B, BE, C, F, GP, HA, MO, P, RB, S, X	WB	ADI-SPS-771
<b>HSP90α/β, mAb (H90-10)</b>	H, M, RB	ICC, IP, WB	ALX-804-808
<b>HSP90β, mAb (K3701)</b>	H, M, R, B, C, GP, HA, P, RB, S	FC, WB	ADI-SPA-843
<b>HSP90β, mAb (K3705)</b>	H, M, R, B, C, CH, HA, GP, P, S	IHC, WB	ADI-SPA-842
<b>TRAP1 (human), mAb (TRAP1-6)</b>	H	ICC, IP, WB	ALX-804-368
<b>UNC45, mAb (AbS1)</b>	H, M, R	WB	ADI-SRA-1800

## Inhibitors

Product	Description	Prod. No.
<b>17-AAG</b>	Less toxic, more potent synthetic derivative of geldanamycin	BML-EI308
<b>17-DMAG</b>	A water soluble, less metabolized analog of 17-AAG	BML-EI337
<b>17-GMB-APA-GA</b>	A maleimido-containing geldanamycin analog suitable for conjugation	BML-EI338
<b>Geldanamycin</b>	A benzoquinoid ansamycin inhibitor of HSP90, which inhibits ATP binding	BML-EI280
<b>Geldanamycin, (biotin conjugate)</b>	Useful for affinity purification of HSP90 client proteins	BML-EI341
<b>Geldanamycin, (FITC conjugate)</b>	Fluorescent HSP90 probe suitable for fluorescent polarization assays	BML-EI361
<b>Herbimycin A</b>	A benzoquinoid ansamycin inhibitor of HSP90, which inhibits ATP binding	BML-EI227
<b>Novobiocin</b>	Binds HSP90 C-terminus rather than the ATP-binding site	BML-A256
<b>Radicalol</b>	Macrocyclic lactone inhibitor of HSP90 with nM affinity	BML-EI285

## Kits, ImmunoSets and Sample Packs

Product	Size	Sample Type	Specificity	Prod. No.
<b>ImmunoSet™ Grp94 ELISA development set</b>	5 x 96 wells	CL, T	H, M, R, C	ADI-960-077
<b>HSP90α (human), EIA kit</b>	1 x 96 wells	CL, S, T	H	ADI-EKS-895
<b>HSP90, Ab sample pack</b>	8 x 25 µg	Not applicable	Multiple species	ADI-PAK-010
<b>HSP90, Ab sample pack with protein standards</b>	10 x 25 µg	Not applicable	Multiple species	ADI-PAK-011

## Proteins

Product	Application	Prod. No.
<b>Activator of HSP90 ATPase 1 (human), (rec.)</b>	Not available	ALX-201-275
<b>Grp94 (canine), (rec.)</b>	WB control	ADI-SPP-766
<b>HOP (human), (rec.)</b>	WB	ALX-201-218
<b>HOP (human), (rec.)</b>	WB control	ADI-SRP-1510
<b>HSP90 (human), (native)</b>	WB	ADI-SPP-770
<b>HSP90 (yeast), (rec.) (His-tag)</b>	WB	ALX-201-138
<b>HSP90α (human), (rec.)</b>	WB control	ADI-SPP-776
<b>HSP90β (human), (rec.)</b>	WB control	ADI-SPP-777
<b>HSP90β (human), (rec.)</b>	WB	ALX-201-147





FIGURE: HSP90, a regulator of cell survival. Inhibition of HSP90 activity by drugs like geldanamycin (GA) destabilizes client proteins which ultimately lead to apoptosis.

# HSP90

## A New Recruit in the War on Cancer



### HSP90: A New Recruit in the War on Cancer

By William J. Welch, Ph.D.  
Professor Emeritus, University of California at San Francisco

Heat shock proteins (HSPs) feature in a multitude of important biological pathways and have come to the forefront of the research field today. Initially described as a curious group of proteins whose levels increased in fruit flies subjected to elevated growth temperatures, HSPs are in fact expressed under most conditions and are essential for growth and survival. Their most important role is to serve as guardians of the cellular proteome. Acting as “molecular chaperones” the various HSPs identify and bind to other proteins that have not yet reached their native folded state. The transient interaction of the chaperone with its target helps to insure against premature folding and/or aggregation of the polypeptide with other macromolecules. Acting together, molecular chaperones increase the fidelity of protein folding and thereby serve to maintain the integrity of the proteome.

Whenever conditions for protein folding/assembly or stability appear unfavorable (e.g. heat shock), the cell down-regulates overall protein synthesis and selectively upregulates chaperone expression to help deal with the problem at hand. Proteins that begin to unfold or aggregate are stabilized and in some cases refolded by the action of the chaperones. In other cases, proteins irreparably damaged are targeted by the chaperones to the ubiquitin-proteasome pathway for degradation. Over the past few years however, investigators have begun to realize there is much more to the story. Specifically, in their role as molecular chaperones, many of the HSPs appear to influence critical events controlling growth, survival and death. In what follows, the biology of one particular stress protein, HSP90, and its role in the development of cancer is presented. Indeed, its participation in so many pathways necessary for tumor formation has made HSP90 (and related family members) a new and exciting target for cancer therapeutics.

As far back as the 1970s, investigators began to realize that despite their designation, most of the HSPs were expressed at high levels in cells maintained under normal growth conditions or from healthy animal tissue. Both genetic and biochemical approaches revealed that deletion of certain HSPs compromised cell growth. Moreover, the expression of some of the HSPs was found to be critical for cell survival under most conditions. One particular stress protein, HSP90, constituted as much as 1-2% of the total cellular protein. Many suspected that such an abundant protein likely served some kind of structural role, perhaps analogous to cytoskeletal components like actin and tubulin.

CONTINUED ON NEXT PAGE




FIGURE: Modified from Xu & Neckers, Clin Cancer Res (2007); 13 (6) 1625-9.



**North/South America**  
ENZO LIFE SCIENCES INTERNATIONAL, INC.  
5120 Butler Pike  
Plymouth Meeting, PA 19462-1202 / USA  
Tel. 1-800-942-0430 / (610) 941-0430  
Fax (610) 941-9252  
info-usa@enzolifesciences.com

**Switzerland & Rest of Europe**  
ENZO LIFE SCIENCES AG  
Industriestrasse 17, Postfach  
CH-4415 Lausen / Switzerland  
Tel. + 41/0 61 926 89 89  
Fax + 41/0 61 926 89 79  
info-ch@enzolifesciences.com

**Benelux**  
ENZO LIFE SCIENCES BVBA  
Melkerrijweg 3  
BE-2240 Zandhoven / Belgium  
Tel. +32/0 3 466 04 20  
Fax +32/0 3 466 04 29  
info-be@enzolifesciences.com

**France**  
ENZO LIFE SCIENCES FRANCE  
c/o Covalab s.a.s  
13, avenue Albert Einstein,  
69100 Villeurbanne / France  
Tel. +33/0 472 440 655  
Fax +33/0 437 484 239  
info-fr@enzolifesciences.com


**Germany**  
ENZO LIFE SCIENCES GmbH  
Marie-Curie-Strasse 8  
DE-79539 Lörrach / Germany  
Tel. +49/0 7621 5500 526  
Toll Free: 0800 6649518  
Fax +49/0 7621 5500 527  
info-de@enzolifesciences.com

**UK & Ireland**  
ENZO LIFE SCIENCES (UK) LTD.  
Palatine House  
Matford Court  
Exeter EX2 8NL / UK  
Tel. 0845 601 1488 (UK customers)  
Tel. +44/0 1392 825900 (overseas)  
Fax +44/0 1392 825910  
info-uk@enzolifesciences.com

For Local Distributors please visit our Website.



## HSP90 Reagents



**FIGURE A:** Western blot analysis of HSP90 (human), (native) (ADI-SPP-770) in lane 1; HSP90 $\alpha$  (human), (rec.) (ADI-SPP-776) in lane 2; and HeLa (heat shocked), (cell lysate) (ADI-LYC-HL101) in lane 3 probed with HSP90 $\alpha$ , mAb (9D2) (ADI-SPA-840).

**FIGURE B:** Structure of Geldanamycin and derivatives.

**FIGURE C:** Western blot analysis of Grp94 (canine), (rec.) (ADI-SPP-766) in lane 2; HeLa, (cell lysate) (ADI-LYC-HL100) in lane 3; liver (mouse), (microsomal extract) (ADI-LYT-MM100) in lane 4; and vero, (cell lysate) in lane 5 probed with Grp94, mAb (9G10) (ADI-SPA-850). (Lane 1 = molecular weight marker).

### Table Abbreviations

#### Application:

AA: ATPase Assay  
EIA: Enzyme Immunoassay  
EM: Electron Microscopy  
FC: Flow Cytometry  
IA: Inhibition Assay  
ICC: Immunocytochemistry  
IF: Immunofluorescence  
IHC: Immunohistochemistry  
IP: Immunoprecipitation  
KA: Kinase Assay  
WB: Western Blot

#### Conjugate:

AP: Alkaline phosphatase  
FITC: Fluorescein isothiocyanate  
HRP: Horseradish peroxidase  
R-PE: R-Phycoerythrin  
  
DyLight 488: DyLight™ 488 is a trademark of Thermo Fisher Scientific, Inc. and its subsidiaries.

#### Product:

pAb: Polyclonal Antibody  
mAb: Monoclonal Antibody


#### Sample Type:

CL: Cell Lysate  
CS: Cell Culture Supernatant  
P: Plasma  
S: Serum  
T: Tissue

#### Specificity:

HO: Horse  
I: Insect  
M: Mouse  
MO: Monkey  
MU: Mussel  
P: Pig  
PL: Plant  
R: Rat  
RB: Rabbit  
S: Sheep  
SC: Scallop  
WM: Water Mold  
X: *Xenopus*  
Y: Yeast

## Discover our Complete HSP Product Range!



Enzo Life Sciences offers a comprehensive range of more than 300 products for HSP & molecular chaperone research. Visit us online for a complete listing or request a free copy of our new *HSP & the Cellular Stress Response* catalog.

Ask for a free copy of this catalog at [www.enzolifesciences.com](http://www.enzolifesciences.com)


While geldanamycin and a few of the other early identified HSP90 inhibitors were found to be too toxic for clinical development, a semi-synthetic analog of geldanamycin, 17-AAG (tanespimycin), was produced and characterized. A number of phase I clinical trials have provided evidence that the compound can indeed inhibit HSP90, as evidenced by the depletion of numerous HSP90 client proteins. These early clinical results show that blocking HSP90 function in vivo results in the inactivation and/or depletion of oncogenic proteins needed to drive tumor growth. Tanespimycin is currently being tested in phase III clinical trials for the treatment of multiple myeloma and other cancers.

Recent studies describing the development and utilization of another HSP90 antagonist fuel further enthusiasm for HSP90 as a cancer target. Shepherdin is a peptidomimetic that was developed to block the interaction of HSP90 with yet another of its client proteins, survivin, an apoptotic inhibitor important in cell growth and survival. A cell permeable derivative of Shepherdin was found to selectively kill tumor-derived cells and diminish the relative amount of numerous HSP90 clients. A subsequent study revealed that Shepherdin not only interacted with HSP90, but also with an HSP90 relative, TRAP-1, located in mitochondria. Here TRAP-1 (and possibly HSP90 as well) normally provides protection against various types of stress-induced apoptosis. Disabling this protective pathway in cancer cells may be one key to the selective anti-tumor effects observed for different HSP90 inhibitors.

All of these studies, both in cell models and animal tumor models, continue to support the idea that inhibition of HSP90 (or its related family members) may prove to be an effective and novel target for cancer therapeutics. As of the early part of 2009, there were at least eight HSP90 inhibitors in clinical development to treat cancer. Some of the compounds being tested are derivatives of the previously mentioned ansamycins, while others are proprietary. Following up on the success of shepherdin, investigators have synthesized ansamycin derivatives designed to accumulate within the mitochondria (called gamitrinibs). Certain trials will test the compound alone, while others will likely test the potential efficacy of the particular HSP90 inhibitor with another more conventional anticancer modality. Already in some instances synergistic effects between HSP90 inhibitors and conventional agents like cisplatin, proteasome inhibitors, and histone deacetylase inhibitors have been observed. This latter result is particularly intriguing considering the fact that HSP90 itself is heavily acetylated and that HSP90 hyperacetylation has been reported to inhibit its chaperone functions. Additionally, HSP90 is heavily phosphorylated and it will therefore be of interest to understand how the multitude of HSP90 post-translational modifications serve to regulate its many chaperone activities and/or client selection.

Progress in our understanding of the stress response and the function of the individual stress proteins has been a remarkable journey. Rather than simply being important players during stress, HSPs serve prominent roles in some of the cell's most basic processes. Their general role as molecular chaperones, protectors of the proteome, is now featured in many areas of active research including aging, neurodegeneration, signaling, immunology and as discussed here cancer. The fascinating role of HSP90 as a key regulator and integrator of signal transduction events, from growth and differentiation to stress and apoptosis, continues to reinforce the idea that this very abundant, heavily modified protein is

in fact a type of “biological buffer.” Consequently, the idea that its buffering capacity may be simply overwhelmed in diseases like cancer makes HSP90 an ideal target for further drug discovery efforts aimed at controlling malignant transformation. As basic research continues to sort out its many client proteins and how they are regulated, and as clinicians continue to design compounds to inhibit its central role in signal transduction events, HSP90 likely will remain a top recruit in the development of new approaches for cancer therapeutics.



**FIGURE:** HSP90 a “drugable” target. Inhibition of HSP90 by geldanamycin (GA) favors the ubiquitination and degradation of client proteins, such as the estrogen receptor (ER).

### Suggested Reading:

Whitesell L and Lindquist S. (2005). HSP90 and the chaperoning of cancer. *Nature Reviews Cancer* 5, 761-772.

Pearl L. H., Prodromou C., and Workman P. (2008). The HSP90 molecular chaperone: An open and shut case for treatment. *Biochem J.* 410, 439-453.

Neckers L (2007). Heat shock protein 90: the cancer chaperone. *J. Biosci.* 32, 517-530.

Kang, B.Y. et al (2007). Regulation of tumor cell mitochondrial homeostasis by an organelle-specific HSP90 chaperone network. *Cell*, 131, 257-270.

Smith D. and Toft D. (2008). The intersection of steroid receptors with molecular chaperones: observations and questions. *Mol. Endocrinol.* 22, 2229-2240.

Lou, K (2009). Hitting HSP90 where it hurts. *Science-Business exchange* 2, 5-6.

HSP90: A New Recruit in the War on Cancer